WINTON GROUP Ltd Grows Stock Position in DexCom, Inc. $DXCM

WINTON GROUP Ltd raised its holdings in DexCom, Inc. (NASDAQ:DXCM) by 226.1% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 136,493 shares of the medical device company’s stock after purchasing an additional 94,631 shares during the period. WINTON GROUP Ltd’s holdings in DexCom were worth $9,193,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in DXCM. California State Teachers Retirement System boosted its stake in shares of DexCom by 6,567.7% during the 2nd quarter. California State Teachers Retirement System now owns 39,176,552 shares of the medical device company’s stock worth $2,638,541,000 after purchasing an additional 38,588,991 shares during the last quarter. Norges Bank acquired a new stake in shares of DexCom during the 4th quarter worth $483,356,000. AQR Capital Management LLC boosted its holdings in DexCom by 597.8% in the fourth quarter. AQR Capital Management LLC now owns 3,102,789 shares of the medical device company’s stock valued at $205,932,000 after acquiring an additional 2,658,158 shares during the last quarter. Legal & General Group Plc acquired a new position in shares of DexCom in the 2nd quarter valued at about $173,237,000. Finally, Deutsche Bank AG purchased a new stake in DexCom during the second quarter worth approximately $164,035,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

Wall Street Analysts Forecast Growth

DXCM has been the subject of a number of analyst reports. Piper Sandler restated an “overweight” rating and issued a $95.00 price target (up from $88.00) on shares of DexCom in a report on Friday, July 31st. Canaccord Genuity Group set a $90.00 price objective on DexCom and gave the stock a “buy” rating in a research note on Monday, August 3rd. Mizuho increased their price objective on shares of DexCom from $90.00 to $95.00 and gave the stock an “outperform” rating in a report on Friday, July 31st. Deutsche Bank Aktiengesellschaft assumed coverage on DexCom in a research note on Tuesday, June 23rd. They issued a “buy” rating and a $86.00 price target for the company. Finally, Bank of America decreased their price objective on shares of DexCom from $100.00 to $80.00 and set a “buy” rating for the company in a report on Monday, May 18th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $88.71.

Insider Buying and Selling

In other DexCom news, EVP Michael Brown sold 1,700 shares of the company’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $75.55, for a total transaction of $128,435.00. Following the completion of the sale, the executive vice president directly owned 106,353 shares of the company’s stock, valued at approximately $8,034,969.15. This represents a 1.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin R. Sayer sold 26,756 shares of the firm’s stock in a transaction dated Monday, July 20th. The stock was sold at an average price of $76.32, for a total transaction of $2,042,017.92. Following the completion of the transaction, the insider owned 328,970 shares of the company’s stock, valued at approximately $25,106,990.40. The trade was a 7.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 65,777 shares of company stock worth $4,950,714 in the last quarter. 0.28% of the stock is currently owned by corporate insiders.

DexCom Stock Performance

Shares of NASDAQ DXCM opened at $83.88 on Thursday. The company has a quick ratio of 1.43, a current ratio of 1.73 and a debt-to-equity ratio of 0.47. The stock has a market capitalization of $31.65 billion, a price-to-earnings ratio of 33.15, a PEG ratio of 1.42 and a beta of 1.42. The stock’s fifty day simple moving average is $82.25 and its 200 day simple moving average is $72.65. DexCom, Inc. has a 52-week low of $54.11 and a 52-week high of $92.59.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, July 30th. The medical device company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.61 by $0.09. DexCom had a return on equity of 35.94% and a net margin of 20.12%.The business had revenue of $1.31 billion during the quarter, compared to the consensus estimate of $1.29 billion. During the same period in the prior year, the business posted $0.48 earnings per share. DexCom’s revenue was up 13.1% compared to the same quarter last year. As a group, sell-side analysts forecast that DexCom, Inc. will post 2.64 earnings per share for the current fiscal year.

DexCom Company Profile

DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems that measure glucose levels in real time. Its technology is designed to help people with diabetes monitor glucose trends and make more informed treatment and lifestyle decisions without relying solely on traditional fingerstick testing.

The company’s products include the Dexcom G7 and Dexcom G6 CGM systems, which use a small wearable sensor, transmitter or integrated sensor, and mobile applications to display glucose data.